RhumbLine Advisers
CAI

RhumbLine Advisers’s Caris Life Sciences CAI Stock Holding History

RhumbLine Advisers’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.76M Buy
98,849
+24,227
+32% +$434K ﹤0.01% 2006
2026
Q1 		$1.33M Buy
74,622
+51,241
+219% +$1.12M ﹤0.01% 2053
2025
Q4 		$631K Buy
23,381
+1,884
+9% +$53.1K ﹤0.01% 2524
2025
Q3 		$650K Buy
+21,497
New +$686K ﹤0.01% 2518

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RhumbLine Advisers's CAI Position: Q2 2026 in Review

RhumbLine Advisers increased its Caris Life Sciences (CAI) stake by 32% in Q2 2026, buying an estimated $434K and bringing the position to 98,849 shares worth $1.76M. The position accounts for ﹤0.01% of the portfolio, ranked #2006.

RhumbLine Advisers first reported a position in CAI in Q3 2025 and has held it in 4 quarters since. 247 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • RhumbLine Advisers held 98,849 shares of Caris Life Sciences worth $1.76M as of Q2 2026.
  • RhumbLine Advisers bought 24,227 Caris Life Sciences shares in Q2 2026, an estimated $434K.
  • Caris Life Sciences made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2006 holding.
  • RhumbLine Advisers first reported a position in Caris Life Sciences in Q3 2025 and has held it in 4 quarters since.
  • 247 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.